We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Consensus vs. actual, and revenue trend
Consensus PT $352.23 · 30 analysts
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
An insider trade (Form 4) was filed.
Stored first · Google News · Yahoo Finance (English)
Norges Bank Buys New Position in Amgen Inc. $AMGN - MarketBeat
Norges Bank Buys New Position in Amgen Inc. $AMGN MarketBeat
Savant Capital LLC Trims Stock Position in Amgen Inc. $AMGN - MarketBeat
Savant Capital LLC Trims Stock Position in Amgen Inc. $AMGN MarketBeat
Eurizon Capital SGR S.p.A. Invests $86.74 Million in Amgen Inc. $AMGN - MarketBeat
Eurizon Capital SGR S.p.A. Invests $86.74 Million in Amgen Inc. $AMGN MarketBeat
Amgen Inc. stock (US0311621009): Upcoming Jefferies appearance keeps focus on US biotech heavyweight - AD HOC NEWS
Amgen Inc. stock (US0311621009): Upcoming Jefferies appearance keeps focus on US biotech heavyweight AD HOC NEWS
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE - PR Newswire
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE PR Newswire
Amgen's CFO and senior execs to speak at Jefferies healthcare event - Stock Titan
Amgen's CFO and senior execs to speak at Jefferies healthcare event Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $5.59 | — | — | $9.42B | — | Scheduled |
| FY2026 Q1 | 2026. 05. 01. | Time TBD | — | $3.2 | — | — | $8.15B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $6.4 | — | — | $24.34B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.17 | — | — | $15.84B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 15. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 05. 04. | Guggenheim | — | Maintain | Neutral → Neutral | — | Guggenheim: Neutral |
| 2026. 05. 02. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 04. 22. | Canaccord Genuity | — | Initiate coverage | — → Hold | — | Canaccord Genuity: Hold |
| 2026. 04. 14. | UBS | — | Maintain | Buy → Buy | — | UBS: Buy |
| 2026. 04. 10. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 700,388 | $229.24B | 0.36% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 71,680 | $25.22B | 0.02% | — | New position |